What specific details in the latest Q3 2025 10-Q support initiating RaniPill HC and RT-114 clinical trials by end-2025?

Rani Therapeutics' latest Q3 2025 10-Q filing and associated press releases provide specific details supporting the initiation of clinical trials for RaniPill HC and RT-114 by the end of 2025.

RT-114 Clinical Trial Initiation:

• Rani Therapeutics explicitly states its plan to "initiate a Phase 1 trial for RT-114 by the end of 2025."1
• This trial is intended to evaluate the safety, tolerability, and pharmacokinetics of RT-114, which is a bispecific GLP-1/GLP-2 receptor agonist delivered orally via the RaniPill capsule.1
• The decision is underpinned by compelling preclinical data, which demonstrated bioequivalence of RT-114 to subcutaneously administered PG-102, with comparable pharmacokinetic profiles and weight loss.1 These nonclinical results provide a robust rationale for advancing RT-114 into clinical development as a potential first-in-class oral anti-obesity therapy.1

RaniPill HC Clinical Testing Initiation:

• The company also stated its intention to "initiate clinical testing of the RaniPill HC by the end of 2025."1
• The RaniPill HC is a high-capacity version of the RaniPill capsule, designed for larger drug payloads.1
• This move is supported by preclinical data demonstrating successful oral delivery of semaglutide (referred to as RT-116) via the RaniPill HC, achieving comparable bioavailability, pharmacokinetics, and weight loss to subcutaneous administration.1

These statements and supporting preclinical data from the Q3 2025 reporting period indicate the company's commitment and rationale for the planned clinical trial initiations.